{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:54:33Z","timestamp":1793318073019,"version":"4.5.0"},"reference-count":49,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a breakthrough treatment for relapsed and refractory multiple myeloma (RRMM). However, these products are complex to deliver, and alternative options are now available. Identifying biomarkers that can predict therapeutic outcomes is crucial for optimizing patient selection. There is a paucity of data evaluating the utility of both serum soluble B-cell maturation antigen (sBCMA) levels and metabolic tumor volume (MTV) at baseline in patients with RRMM undergoing CAR-T therapy. We identified a cohort of 183 patients with available serum to measure sBCMA and\/or pretreatment MTV, derived from positron emission tomography\u2013computed tomography scans obtained per standard of care. Expectedly, high pretreatment levels of sBCMA correlated with other established markers of tumor burden (eg, bone marrow plasma cells and \u03b22 microglobulin) and inflammation and were highly prognostic for CAR-T\u2013related toxicities and inferior progression-free survival (PFS). High MTV values were also associated with shorter PFS and inferior overall survival. The poor correlation observed between these 2 measures prompted evaluation of those with discordant results, identifying that those with low sBCMA and high MTV frequently had low\/absent BCMA expression on plasma cells and suboptimal response. Our findings highlight the potential utility of sBCMA and MTV to facilitate more personalized treatment strategies in the management of RRMM eligible for BCMA-directed CAR-T.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024024965","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T15:22:04Z","timestamp":1733757724000},"page":"1645-1657","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":49,"title":["Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0662-6480","authenticated-orcid":false,"given":"Ciara L.","family":"Freeman","sequence":"first","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald","family":"Noble","sequence":"additional","affiliation":[{"name":"2Department of Clinical Science, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Menges","sequence":"additional","affiliation":[{"name":"2Department of Clinical Science, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Villanueva","sequence":"additional","affiliation":[{"name":"3Morsani College of Medicine, University of South Florida, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9720-2421","authenticated-orcid":false,"given":"Justyn Y.","family":"Nakashima","sequence":"additional","affiliation":[{"name":"4Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6885-3320","authenticated-orcid":false,"given":"Nicholas B.","family":"Figura","sequence":"additional","affiliation":[{"name":"4Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2712-7189","authenticated-orcid":false,"given":"Rolf Petter","family":"Tonseth","sequence":"additional","affiliation":[{"name":"5Molecular Imaging and Therapy Program, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6115-3348","authenticated-orcid":false,"given":"Dietrich","family":"Werner Idiaquez","sequence":"additional","affiliation":[{"name":"6Department of Hematopathology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Skelson","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Smith","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julieta","family":"Abraham-Miranda","sequence":"additional","affiliation":[{"name":"2Department of Clinical Science, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2450-4022","authenticated-orcid":false,"given":"Salvatore","family":"Corallo","sequence":"additional","affiliation":[{"name":"2Department of Clinical Science, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"De Avila","sequence":"additional","affiliation":[{"name":"2Department of Clinical Science, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar A.","family":"Castaneda Puglianini","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9945-4381","authenticated-orcid":false,"given":"Hien","family":"Liu","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Alsina","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-7924","authenticated-orcid":false,"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4178-8888","authenticated-orcid":false,"given":"Kenneth H.","family":"Shain","sequence":"additional","affiliation":[{"name":"7Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Baz","sequence":"additional","affiliation":[{"name":"7Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Blue","sequence":"additional","affiliation":[{"name":"7Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0999-1771","authenticated-orcid":false,"given":"Ariel","family":"Grajales-Cruz","sequence":"additional","affiliation":[{"name":"7Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3818-1762","authenticated-orcid":false,"given":"John M.","family":"Koomen","sequence":"additional","affiliation":[{"name":"8Department of Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reginald M.","family":"Atkins","sequence":"additional","affiliation":[{"name":"2Department of Clinical Science, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariosto","family":"S. Silva","sequence":"additional","affiliation":[{"name":"9Department of Metabolism and Physiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7430-2226","authenticated-orcid":false,"given":"Jongphil","family":"Kim","sequence":"additional","affiliation":[{"name":"10Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5598-4727","authenticated-orcid":false,"given":"Yoganand","family":"Balagurunathan","sequence":"additional","affiliation":[{"name":"11Department of Machine Learning, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2025041015222626300_bib1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10297","key":"2025041015222626300_bib2","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"2025041015222626300_bib3","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2025041015222626300_bib4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2025041015222626300_bib5","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2025041015222626300_bib6","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/bjh.18185","article-title":"How I treat triple-class refractory multiple myeloma","volume":"198","author":"Costa","year":"2022","journal-title":"Br J Haematol"},{"issue":"14","key":"2025041015222626300_bib7","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1200\/JCO.23.02232","article-title":"Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma","volume":"42","author":"Gagelmann","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2025041015222626300_bib8","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.3324\/haematol.2022.282510","article-title":"Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients","volume":"108","author":"Gagelmann","year":"2023","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2025041015222626300_bib9","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood-2021-148375","article-title":"Baseline correlates of complete response to idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy in patients with relapsed and refractory multiple myeloma: subanalysis of the KarMMa trial","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"issue":"suppl 16","key":"2025041015222626300_bib10","doi-asserted-by":"crossref","first-page":"8021","DOI":"10.1200\/JCO.2022.40.16_suppl.8021","article-title":"Correlative analysis to define patient profiles associated with manufacturing and clinical endpoints in relapsed refractory multiple myeloma patients treated with idecabtagene vicleucel (ide-cel; bb2121), an anti-BCMA CAR T-cell therapy","volume":"40","author":"Julie Rytlewski","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"19","key":"2025041015222626300_bib11","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"2025041015222626300_bib12","doi-asserted-by":"crossref","first-page":"e005678","DOI":"10.1136\/jitc-2022-005678","article-title":"Dose-response correlation for CAR-T cells: a systematic review of clinical studies","volume":"10","author":"Rotte","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"2025041015222626300_bib13","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41598-021-04296-3","article-title":"The differential effects of tumor burdens on predicting the net benefits of ssCART-19 cell treatment on r\/r B-ALL patients","volume":"12","author":"Li","year":"2022","journal-title":"Sci Rep"},{"issue":"2","key":"2025041015222626300_bib14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"issue":"9","key":"2025041015222626300_bib15","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"2025041015222626300_bib16","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Haematologica"},{"key":"2025041015222626300_bib17","doi-asserted-by":"crossref","first-page":"1611171","DOI":"10.3389\/pore.2023.1611171","article-title":"Soluble B-cell maturation antigen as a monitoring marker for multiple myeloma","volume":"29","author":"Wiedemann","year":"2023","journal-title":"Pathol Oncol Res"},{"key":"2025041015222626300_bib18","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.leukres.2019.04.008","article-title":"Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells","volume":"81","author":"Chen","year":"2019","journal-title":"Leuk Res"},{"issue":"23","key":"2025041015222626300_bib19","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"issue":"19","key":"2025041015222626300_bib20","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1158\/1078-0432.CCR-15-0396","article-title":"PET\/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma","volume":"21","author":"Zamagni","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2025041015222626300_bib21","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.eclinm.2023.102017","article-title":"Impact of minimal residual disease standardised assessment by FDG-PET\/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial","volume":"60","author":"Zamagni","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"1","key":"2025041015222626300_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13139-017-0507-4","article-title":"PERCIST in perspective","volume":"52","author":"O, J.H.","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"issue":"14","key":"2025041015222626300_bib23","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"2025041015222626300_bib24","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1148\/radiol.2016142043","article-title":"Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0","volume":"280","author":"O","year":"2016","journal-title":"Radiology"},{"issue":"3","key":"2025041015222626300_bib25","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.17338","article-title":"Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations","volume":"194","author":"Rosi\u00f1ol","year":"2021","journal-title":"Br J Haematol"},{"issue":"S1","key":"2025041015222626300_bib26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/hon.2065","article-title":"V.\u00a0Molecular classification and risk stratification of myeloma","volume":"31","author":"Bergsagel","year":"2013","journal-title":"Hematol Oncol"},{"key":"2025041015222626300_bib27","author":"Swerdlow","year":"2017"},{"issue":"4","key":"2025041015222626300_bib28","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 1","key":"2025041015222626300_bib29","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1182\/blood-2023-181762","article-title":"Real world outcomes with idecabtagene vicleucel (ide-cel) CAR-T cell therapy for relapsed\/refractory multiple myeloma","volume":"142","author":"Sidana","year":"2023","journal-title":"Blood"},{"issue":"282","key":"2025041015222626300_bib30","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"issue":"3","key":"2025041015222626300_bib31","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother Rep"},{"issue":"2","key":"2025041015222626300_bib32","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J\u00a0Roy Stat Soc B"},{"issue":"suppl 16","key":"2025041015222626300_bib33","article-title":"Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (cilta-cel) for relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Hansen","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2025041015222626300_bib34","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1158\/2643-3230.BCD-23-0044","article-title":"Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel","volume":"4","author":"Paiva","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"2025041015222626300_bib35","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood.2023023557","article-title":"Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma","volume":"144","author":"Firestone","year":"2024","journal-title":"Blood"},{"issue":"4","key":"2025041015222626300_bib36","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat Med"},{"issue":"2","key":"2025041015222626300_bib37","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1016\/j.jtct.2023.12.239","article-title":"Real world outcomes of older adults and frail patients with relapse\/refractory multiple myeloma receiving idecabtagene vicleucel","volume":"30","author":"Akhtar","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"2025041015222626300_bib38","doi-asserted-by":"crossref","first-page":"283.e1","DOI":"10.1016\/j.jtct.2023.12.010","article-title":"Simple score of albumin and CRP predicts high-grade toxicity in patients with multiple myeloma receiving CAR-T therapy","volume":"30","author":"Akhtar","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"2025041015222626300_bib39","doi-asserted-by":"crossref","first-page":"101628","DOI":"10.1016\/j.jgo.2023.101628","article-title":"Safety\u00a0and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: a systematic review and meta-analysis","volume":"15","author":"Akhtar","year":"2024","journal-title":"J\u00a0Geriatr Oncol"},{"issue":"25","key":"2025041015222626300_bib40","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood.2024026212","article-title":"Impact of soluble BCMA and non\u2013T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2025041015222626300_bib41","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2025041015222626300_bib42","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1007\/s00259-024-06668-z","article-title":"Artificial intelligence\u2013based, volumetric assessment of the bone marrow metabolic activity in [18F]FDG PET\/CT predicts survival in multiple myeloma","volume":"51","author":"Sachpekidis","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"2025041015222626300_bib43","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s00277-021-04560-6","article-title":"Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy","volume":"100","author":"Iacoboni","year":"2021","journal-title":"Ann Hematol"},{"issue":"21","key":"2025041015222626300_bib44","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.3390\/cancers14215221","article-title":"A\u00a0deep learning-aided automated method for calculating metabolic tumor volume in diffuse large B-cell lymphoma","volume":"14","author":"Kuker","year":"2022","journal-title":"Cancers"},{"issue":"12","key":"2025041015222626300_bib45","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.2967\/jnumed.121.263501","article-title":"18F-FDG PET maximum-intensity projections and artificial intelligence: a win-win combination to easily measure prognostic biomarkers in DLBCL patients","volume":"63","author":"Girum","year":"2022","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"2025041015222626300_bib46","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2967\/jnumed.120.242412","article-title":"Deep-learning 18F-FDG uptake classification enables total metabolic tumor\u00a0volume estimation in diffuse large B-cell lymphoma","volume":"62","author":"Capobianco","year":"2021","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"2025041015222626300_bib47","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","article-title":"Low expression of hexokinase-2 is associated with false-negative FDG\u2013positron emission tomography in multiple myeloma","volume":"130","author":"Rasche","year":"2017","journal-title":"Blood"},{"key":"2025041015222626300_bib48","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3389\/fonc.2020.622501","article-title":"PET\/CT in multiple myeloma:\u00a0beyond FDG","volume":"10","author":"Matteucci","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"2025041015222626300_bib49","doi-asserted-by":"crossref","first-page":"e2101565","DOI":"10.1002\/adhm.202101565","article-title":"Anti-BCMA immuno-NanoPET radiotracers for improved detection of multiple myeloma","volume":"11","author":"Thomas","year":"2022","journal-title":"Adv Healthc Mater"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/15\/1645\/2367952\/blood_bld-2024-024965-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/15\/1645\/2367952\/blood_bld-2024-024965-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T11:22:39Z","timestamp":1744284159000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/15\/1645\/534402\/Tumor-burden-quantified-by-soluble-B-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":49,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025,4,10]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024024965","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]}}}